Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Article A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHAuthored by Nathan Reiff. Article Posted: 2/12/2026. 
Key Takeaways - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight beyond what investors might glean from FDA approvals or other regulatory notices. When healthcare companies release earnings on the same day, it can be a busy time for investors sorting through the news and planning trades. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors looking to make informed decisions based on these updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now U.K.-based pharma giant AstraZeneca closed out 2025 by cementing its position as a leading provider of cancer medicines, which accounted for about 44% of product sales in the fourth quarter. Sales of oncology drugs such as Imfinzi and Enhertu grew as much as 48% year-over-year (YOY), helping to propel total revenue up 8.6% to $58.7 billion for the quarter. After-tax profits surged alongside revenue, rising to $10.2 billion from $7 billion in the prior-year quarter. The company's board declared a second interim dividend that was 7 cents per share higher than the year-ago payout. Investors also have near-term catalysts as AstraZeneca advances dozens of drugs through clinical testing. Management said roughly 20 Phase 3 readouts are expected in 2026, and the firm expects solid increases to both total revenue and core earnings per share (EPS) for the full year. In the hours after its strong earnings report, AZN shares climbed about 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street question the firm's valuation: the consensus price target of $95.75 implies roughly a 51% downside from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Earnings and Margin Pressures Edwards, a maker of replacement heart valves and related surgical devices and monitoring systems, reported largely positive Q4 2025 results, including 13.3% YOY sales growth driven by strong transcatheter aortic valve replacement (TAVR) momentum and demand for the latest SAPIEN valve. However, adjusted EPS missed analyst expectations and gross profit margin declined 0.8% YOY, highlighting some near-term pressure on profitability. Despite the mixed signals, Edwards remains confident it can meet its prior 2026 outlook, which called for sales growth of 8% to 10% YOY and EPS between $2.90 and $3.05. EW shares rose about 4% in after-hours trading, trading above $80 following the announcement. About two-thirds of analysts covering EW rate the stock a Buy, and the consensus price target implies roughly 25% upside to $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, which makes replacement systems and implants for joint and bone disorders, reported EPS of $2.42—four cents above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Demand for Zimmer's orthopedic products remains strong, supporting top- and bottom-line growth. The company is also shifting its focus more toward U.S. sales, which account for roughly 60% of its business. With insured-patient utilization rising, near-term demand for Zimmer's products is expected to stay elevated. Still, Zimmer will likely face headwinds from tariffs that could pressure EPS and revenue in 2026. Management issued conservative guidance in the latest earnings report, calling for adjusted EPS of $8.30 to $8.45 and free cash flow improvement of 8% to 10%. Analysts remain divided on Zimmer, with the company generally rated a Hold despite about 15% projected upside in consensus forecasts.
| 
